VaxNewMo is developing next generation conjugate vaccines against bacterial diseases using its patented conjugating enzyme technology. Our conjugating enzyme technology is faster, more natural, and more reliable than methods used by pharmaceutical companies.

For more information, visit VaxNewMo or follow their updates on:



  • $3m

VaxNewMo Articles

In 2019, BioGenerator Invested $3.2 Million in 16 Bioscience Companies in St. Louis

VaxNewMo’s Vaccine Breakthrough Published in Nature

A “No” from Arch Grants Isn’t a “No” to Your Business

Bioscience Startup Founders: Expect Bumps in the Road From Academic to Entrepreneur

Meet the Next Generation of Job Creators Winning in St. Louis

18 Startups Win $50,000 Each To Locate Their Business In St Louis